Across the recent three months, 10 analysts have shared their insights on Viridian Therapeutics VRDN, expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 2 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Viridian Therapeutics, revealing an average target of $37.2, a high estimate of $47.00, and a low estimate of $27.00. Observing a downward trend, the current average is 0.05% lower than the prior average price target of $37.22.
Understanding Analyst Ratings: A Comprehensive Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive Viridian Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Serge Belanger | Needham | Maintains | Buy | $38.00 | $38.00 |
| Derek Archila | Wells Fargo | Announces | Equal-Weight | $27.00 | - |
| Gregory Renza | RBC Capital | Raises | Outperform | $47.00 | $44.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $34.00 | $34.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $34.00 | $34.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $44.00 | $44.00 |
| Serge Belanger | Needham | Maintains | Buy | $38.00 | $38.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $34.00 | $27.00 |
| Serge Belanger | Needham | Maintains | Buy | $38.00 | $38.00 |
| Serge Belanger | Needham | Maintains | Buy | $38.00 | $38.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Viridian Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viridian Therapeutics compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Viridian Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Viridian Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Viridian Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Breaking Down Viridian Therapeutics's Financial Performance
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Viridian Therapeutics showcased positive performance, achieving a revenue growth rate of 19.44% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Viridian Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -89173.26%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Viridian Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -18.08%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Viridian Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.3%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Viridian Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
The Basics of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
